Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL

GlobeNewswire June 27, 2014

Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company

GlobeNewswire June 4, 2014

Genmab Announces Ofatumumab Development Plans in RRMS and NMO

GlobeNewswire May 30, 2014

GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy

GlobeNewswire May 23, 2014

GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

GlobeNewswire May 19, 2014

Genmab Announces Financial Results for the First Quarter of 2014

GlobeNewswire May 7, 2014

Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance

GlobeNewswire May 1, 2014

First Quarter 2014 Net Sales Figures for Arzerra

GlobeNewswire April 30, 2014

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate

PR Newswire April 17, 2014

GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate

GlobeNewswire April 17, 2014

Passing of Genmab A/S' Annual General Meeting

GlobeNewswire April 9, 2014

Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire March 26, 2014

Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma

GlobeNewswire March 5, 2014

Genmab 2013 Annual Report

GlobeNewswire March 4, 2014

Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures

Globe Newswire February 5, 2014

Major Shareholder Announcement

Globe Newswire January 29, 2014

Genmab Announces DuoBody Platform Collaboration With Lilly

Globe Newswire January 14, 2014

GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)

Globe Newswire December 17, 2013

Major Shareholder Announcement

Globe Newswire December 11, 2013

Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved

Globe Newswire December 6, 2013